<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083390</url>
  </required_header>
  <id_info>
    <org_study_id>NUT-3/NAS</org_study_id>
    <nct_id>NCT05083390</nct_id>
  </id_info>
  <brief_title>Norursodeoxycholic Acid vs. Placebo in NASH</brief_title>
  <official_title>Double-blind, Randomised, Placebo-controlled, Phase IIb Trial on the Efficacy and Safety of Norursodeoxycholic Acid Tablets in Patients With Non-alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomised, multi-centre, placebo-controlled, comparative, phase IIb&#xD;
      trial. The trial will be conducted with three treatment groups in the form of a parallel&#xD;
      group comparison and will serve to compare oral treatment with either 1500 mg/d or 1000 mg/d&#xD;
      norUDCA tablets vs. placebo tablets for the treatment of NASH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with resolution of NASH, assessed by centrally scored liver histology, and no worsening of fibrosis AND/OR improvement of fibrosis, and no worsening of NAS</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">363</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>norUrsodeoxycholic acid 1500 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 film-coated tablets once daily for 72 weeks containing in total norUrsodeoxycholic acid 1500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>norUrsodeoxycholic acid 1000 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 film-coated tablets once daily for 72 weeks containing in total norUrsodeoxycholic acid 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to norUrsodeoxycholic acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 film-coated tablets once daily for 72 weeks containing placebo to norUrsodeoxycholic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norUrsodeoxycholic acid</intervention_name>
    <description>500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day</description>
    <arm_group_label>Placebo to norUrsodeoxycholic acid</arm_group_label>
    <arm_group_label>norUrsodeoxycholic acid 1000 mg/day</arm_group_label>
    <arm_group_label>norUrsodeoxycholic acid 1500 mg/day</arm_group_label>
    <other_name>norucholic acid</other_name>
    <other_name>norUDCA</other_name>
    <other_name>NCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be willing to participate in the study and provide written informed consent&#xD;
&#xD;
          -  Male or female patients â‰¥ 18 and &lt; 75 years&#xD;
&#xD;
          -  Centrally assessed histological evidence of NASH and liver fibrosis&#xD;
&#xD;
          -  Women of childbearing potential agree to use a highly effective method of birth&#xD;
             control during the entire duration of the trial and for 4 weeks following the last&#xD;
             dose of trial treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients taking prohibited medications&#xD;
&#xD;
          -  Presence of liver cirrhosis&#xD;
&#xD;
          -  Type 1 diabetes or uncontrolled Type 2 diabetes&#xD;
&#xD;
          -  History or presence of any other significant concomitant liver diseases&#xD;
&#xD;
          -  History of liver transplantation&#xD;
&#xD;
          -  BMI &gt;45 kg/m^2&#xD;
&#xD;
          -  Any known relevant infectious disease (e.g., active tuberculosis, acquired&#xD;
             immunodeficiency syndrome [AIDS]-defining diseases)&#xD;
&#xD;
          -  Abnormal renal function (glomerular filtration rate estimated from cystatin C &lt; 30&#xD;
             ml/min) at screening visit&#xD;
&#xD;
          -  Any active malignant disease (except for basal cell carcinoma)&#xD;
&#xD;
          -  Existing or intended pregnancy or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Trauner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of Internal Medicine III</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Stiess, PhD</last_name>
    <phone>++49-761-1514</phone>
    <phone_ext>0</phone_ext>
    <email>zentrale@drfalkpharma.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Internal Medicine III</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Trauner, MD</last_name>
      <phone>0043 (0)1 40400</phone>
      <phone_ext>47440</phone_ext>
      <email>michael.trauner@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is not yet decided which data will be made available. Neither a time frame can be indicated yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

